Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer's Disease: A Recent Update.

Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer's Disease: A Recent Update. CNS Neurol Disord Drug Targets. 2020 Aug 18;: Authors: Pandey M, Choudhury H, Verma RK, Chawla V, Bhattamisra SK, Gorain B, Raja MAG, Amjad MW Abstract Alzheimer Association Report (2019) stated that the 6th primary cause of death in the USA is Alzheimer's disease (AD) which leads to behaviour and cognitive impairment. Nearly 5.8 million peoples of all ages in the USA have suffered from this disease, including 5.6 million elderly populations. The statistics of the progression of this disease is similar to the global scenario. Still, the treatment of AD is limited to a few conventional oral drugs which often fail to deliver the adequate amount of drug in the brain. The reduction in the therapeutic efficacy of anti-AD drug is due to poor solubility, existence to the blood-brain barrier and low permeability. In this context, nasal drug delivery emerges as a promising route for the delivery of large and small molecular drugs for the treatment of AD. This promising pathway delivers the drug directly into the brain via an olfactory route which leads to the low systemic side effect, enhanced bioavailability, and higher therapeutic efficacy. However, few setbacks such as mucociliary clearance and poor drug mucosal permeation limit its translation from the laboratory to the clinic. Above stated limitation could be overcome by the adaption of nanopar...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research